NEW YORK, June 14 (Reuters) - For millions of heart patients, a pair of new blood thinners have been heralded as the first replacements in 60 years for warfarin, a pill whose hardships and risks have ...
Xarelto has already snagged an approval for preventing blood clots after orthopedic surgery, but that indication pales next to the $20 billion market that is emerging for therapies that can replace ...
As Johnson & Johnson ($JNJ) builds the blockbuster pedigree of Xarelto, an FDA reviewer has given the thumbs-up to the new clot-busting drug as a treatment for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results